- Home
- PLUR vs GNTA Comparison
PLUR vs GNTA Comparison
Compare PLUR & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | GNTA |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Israel | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 34.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLUR | GNTA |
|---|---|---|
| Price | $3.31 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 9.9K | ★ 3.0M |
| Earning Date | 02-06-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,326,000.00 | N/A |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 121.74 | N/A |
| 52 Week Low | $2.82 | $1.06 |
| 52 Week High | $7.13 | $10.00 |
Technical Indicators
Market Signals| Indicator | PLUR | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 31.60 |
| Support Level | $3.00 | $1.26 |
| Resistance Level | $3.50 | $1.70 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 65.00 | 1.22 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.